Balanced news tone
News Sentiment
TRAX sentiment intelligence
First Tracks Biotherapeutics news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+87.8% over one week, +105.4% over four weeks, trend inactive, and materially above fair value.
First Tracks Biotherapeutics (TRAX) News Flow
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 29 Mar 2026 07:00
- Source
- TradingView
First Tracks Biotherapeutics, the Planned Spin-Off of
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Mar 2026 07:00
- Source
- GlobeNewswire
First Tracks Biotherapeutics Secures $80 Million in Private Placement, Launching with $180 Million in Cash Post Spin-Off from AnaptysBio
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 27 Mar 2026 07:00
- Source
- Quiver Quantitative
First Tracks targets $180M cash at launch after $145M financing
- Tone
- Neutral 50/100
- Event
- Balance sheet
- Published
- 27 Mar 2026 07:00
- Source
- Stock Titan